Coming 2019

Speaker

Expand/Collapse

Amy S. Rosenberg
Supervisory Medical Officer and Division Director, Office of Biotechnology Products
CDER/FDA

Day Two

Thursday April 26, 2018

15.30 | Chair's Closing Remarks & End of the Summit, Followed by Afternoon Refreshments & Networking

14.00 | Panel Discussion: How to Develop Transferable and Durable Antigen-Specific Immune Tolerance Therapies?

11.45 | Immune Tolerance Induction: Clinical Urgency as a Factor in Dictating Approach

09.00 | Chair's Opening Remarks

Lachy McLean
VP, Head of Clinical & Translational Sciences, Immunology
Takeda Pharmaceuticals

Day One

Wednesday April 25, 2018

16.15 | Pannel Discussion: Pre-Clinical Proof of Concept In Vivo: Realistic or a Dream?

Day Two

Thursday April 26, 2018

14.45 | Panel Discussion: How to Develop Commercially Viable Antigen-Specific Immune Tolerance Therapies?

Jose M. Carballido
Executive Director & Translational Research Fellow
Novartis

Day One

Wednesday April 25, 2018

11.00 | Challenges and Opportunities to Develop Immune Tolerance Approaches to Cure Type 1 Diabetes

Day Two

Thursday April 26, 2018

14.00 | Panel Discussion: How to Develop Transferable and Durable Antigen-Specific Immune Tolerance Therapies?

Arpita Maiti
Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome
Pfizer

Day One

Wednesday April 25, 2018

17.00 | Chair's Closing Remarks & End of Day One

09.35 | Accessing Innovation in Antigen-Specific Immune Tolerance – A Big Pharma View

09.00 | Chair’s Opening Remarks

Day Two

Thursday April 26, 2018

14.45 | Panel Discussion: How to Develop Commercially Viable Antigen-Specific Immune Tolerance Therapies?

Jack A. Ragheb
Senior Medical Fellow for Immunology
Eli Lilly & Co

Day One

Wednesday April 25, 2018

11.50 | The Potential of B Cell Tolerance in Autoimmunity

Lawrence Steinman
Professor at Stanford University & Executive Chairman of the Board
Tolerion

Day One

Wednesday April 25, 2018

09.10 | The Underlying Causes of Autoimmunity: How to Develop Broader Immune Modulation Models?

Day Two

Thursday April 26, 2018

12.35 | Case Study: Antigen- Specific Tolerance for Type 1 Diabetes, Neuromyelitis Optica, Myasthenia Gravis and Protein Replacement Therapy

Matthias von Herrath
Professor at the La Jolla Institute for Allergy and Immunology; VP & Head of Type 1 Diabetes R&D Center Seattle
Novo Nordisk

Day Two

Thursday April 26, 2018

14.45 | Panel Discussion: How to Develop Commercially Viable Antigen-Specific Immune Tolerance Therapies?

09.10 | Pathology of Human Type 1 Diabetes and New Antigenic Interventions

Julia Greenstein
VP, Research Strategy
JDRF

Day One

Wednesday April 25, 2018

11.25 | The Potential of Antigen-Specific Therapies as Part of a Combination Approach to Type 1 Diabetes Therapy

Day Two

Thursday April 26, 2018

14.00 | Panel Discussion: How to Develop Transferable and Durable Antigen-Specific Immune Tolerance Therapies?

David W. Scott
Professor of Medicine & Vice Chair for Research
USUHS

Kei Kishimoto
CSO
Selecta Biosciences Inc.

Day Two

Thursday April 26, 2018

12.10 | Case Study: Pre-clinical & Clinical Development of Tolerogenic Nanoparticles to Mitigate Immunogenicity Against Biologic Drugs

Daniel Rotrosen
Director, Division of Allergy, Immunology & Transplantation
NIAID/NIH

Day One

Wednesday April 25, 2018

10.00 | Overview of NIAID- Sponsored Research on Antigen-Specific Immune Tolerance

Day Two

Thursday April 26, 2018

14.45 | Panel Discussion: How to Develop Commercially Viable Antigen-Specific Immune Tolerance Therapies?

Timm H. Jessen
CEO
Topas Therapeutics

Day One

Wednesday April 25, 2018

14.35 | Case Study: Generation of Antigen-Specific Immune Tolerance by Harnessing the Liver’s Natural Capabilities

Day Two

Thursday April 26, 2018

14.00 | Panel Discussion: How to Develop Transferable and Durable Antigen-Specific Immune Tolerance Therapies?

Francisco J. Quintana
Associate Professor at Harvard; Co Founder & Director
AnTolRx

Day One

Wednesday April 25, 2018

16.15 | Pannel Discussion: Pre-Clinical Proof of Concept In Vivo: Realistic or a Dream?

Day Two

Thursday April 26, 2018

10.00 | Case Study: Nanoparticles for the Induction of Antigen-Specific Tolerance

Jonathan Zalevsky
SVP Research & CSO
Nektar Therapeutics

Day One

Wednesday April 25, 2018

15.25 | Case Study: NKTR-358: A Selective Regulatory T Cell Inducing Agent for the Treatment of Autoimmune and Inflammatory Diseases

Wojciech Jankowski
Research Reviewer, Center for Biologics Evaluation & Research
CBER/FDA

Day Two

Thursday April 26, 2018

09.35 | Case Study: Non-Clinical Assessments of Immunogenicity

Todd Zion
President & CEO
Akston Biosciences

Day One

Wednesday April 25, 2018

16.15 | Pannel Discussion: Pre-Clinical Proof of Concept In Vivo: Realistic or a Dream?

Day Two

Thursday April 26, 2018

10.25 | Case Study: Targeting Insulin-Specific B Cells To Prevent Type 1 Diabetes

Stephan Kontos
Co-Founder & VP Research
Anokion and Kanyos Bio

Day Two

Thursday April 26, 2018

10.50 | Case Study: Harnessing Natural Tolerance Pathways with Targeted Delivery Technologies Induces Robust Antigen-Specific Tolerance

Stephen Miller
Professor at Northwestern University Medical School & Co-founder
Cour Pharmaceutical

Day One

Wednesday April 25, 2018

15.00 | Case Study: From Bench to Bedside: An Antigen-Encapsulating Nanoparticle-based Negative T Cell Vaccine for Tolerogenic Therapy of Autoimmune Disease

Wanjun Chen
Senior Investigator (prof.) and Chief
NIDCR/NIH

Day One

Wednesday April 25, 2018

15.50 | Case Study: Induction of Autoantigen-Specific Regulatory T Cells In Vivo to Treat Autoimmunity

Clare M. Baecher- Allan
Assistant Professor of Neurology
Harvard University

Day One

Wednesday April 25, 2018

13.15 | Case Study: Key Lessons Learned from Regulatory T Cells for Cellular Therapy

Finola Moore
Project Leader & Senior Scientist
SQZ Biotech

Day One

Wednesday April 25, 2018

16.15 | Pannel Discussion: Pre-Clinical Proof of Concept In Vivo: Realistic or a Dream?

13.40 | Case Study: Efficient Intracellular Microfluidic Delivery into RBCs to Induce Tolerance